Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2017

View Archived Issues

Roche describes novel HBsAg secretion inhibitors

Bristol-Myers Squibb presents new TGF-beta receptor type-1 inhibitors

Eisai reflects on key achievements of third quarter of fiscal 2016

Novartis initiates phase I trial of HKT-288 in solid tumors

Reduced SOD1 gene expression as a biomarker in patients with primary glaucoma

Ariad files for European marketing approval of brigatinib

FDA approves IND for light-activated drug to treat ocular melanoma

Researchers announce discovery of first blood biomarker for MS

Galena reports positive outcome of futility assessment of NeuVax trials

Sobi announces potential sale of the partner products business area

In situ activation of platelets enhances anti-PD-L1 delivery and reduces post-surgical recurrence

Activation of microRNA-1182 may induce melanoma apoptosis

Exosome Diagnostics and Merck KGaA sign agreement to advance drug development efforts

First-in-human trial demonstrates efficacy of 68Ga-BBN-RGD for prostate cancer diagnosis and staging

Sirnaomics initiates first-in-human study of STP-705

Bayer discloses novel isocitrate dehydrogenase (NADP+) inhibitors

Institute of Experimental Botany identifies apoptosis inducers/ROS inhibitors

Following successful phase I testing, CF drug SPX-101 will move to phase II

FDA lifts partial clinical hold on phase III study of DCVax-L

Takeda discovers prostanoid EP4 receptor antagonists

Renova announces development plans for stresscopin

Enanta patents novel benzodiazepine derivatives

BioTime acquires ophthalmology assets from University of Pittsburgh

Isogenica grants license to Maverick Therapeutics for antibody technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...